NEW YORK (GenomeWeb News) – The National Cancer Institute has issued three new grant opportunities funding emerging cancer technologies through its Innovative Molecular Analysis Technologies Program (IMAT).
The aim of the IMAT program is to fund research that generates tools and methods that enable cancer researchers to develop new tools for detecting, diagnosing, and treating cancer.
The "Innovative Technology Development for Cancer Research" program will grant a total of $5 million in 2010 to up to 15 investigators involved in "exploratory research projects focused on the inception and development of early stage, highly innovative, transformative cancer-relevant technologies," according to NCI.
These grants will give up to $500,000 over three years to highly innovative technologies with the potential to accelerate or enhance research into cancer biology, prevention, treatment, and diagnosis. These would include projects in any area of cancer-related technologies, such as tools that target molecular, atomic, sub-cellular, and cellular levels of detection and analysis.
Areas of interest include, but are not limited to: early cancer detection and risk assessment tools; methods of distinguishing, assessing, and monitoring cancer stage and progression; and robust technologies adapted for use in epidemiological research.
Another grant "Application and Early Stage Development of Emerging Technologies in Cancer Research," will give around $2.3 million in 2010 for researchers who propose using emerging analytical technologies as lab or clinical tools.
The program will give up to $275,000 in support over two years to fund projects that could broadly impact cancer-relevant research. The proposed studies should have the potential to have high impact value, even if they carry some risk.
The third grant program, "Validation and Advanced Development of Emerging Technologies for Cancer Research," will give $2.25 million to support up to 7 investigators using technologies where the proof-of-principle or methodology has already been established.
Granting up to $300,000 per year for a three-year period, this program will support research projects that propose developing innovative molecular and cellular analysis tools that could be intended for use in in vitro, in situ, in silico, or in vivo applications, and may be targeted for the needs of basic, translational, epidemiology, and clinical cancer research.